ArticleArXiv2025
Low-N Protein Activity Optimization with FolDE.
Article in ArXiv, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Proteins are traditionally optimized through the costly construction and measurement of many mutants. Active Learning-assisted Directed Evolution (ALDE) alleviates that cost by predicting the best improvements and iteratively testing mutants to inform predictions. However, existing ALDE methods face a critical limitation: selecting the highest-predicted mutants in each round yields homogeneous training data insufficient for accurate prediction models in subsequent rounds. Here we present FolDE, an ALDE method designed to maximize end-of-campaign success. In simulations across 20 protein targets, FolDE discovers 23% more top 10% mutants than the best baseline method (p=0.005) and is 55% more likely to find top 1% mutants. FolDE achieves this primarily through naturalness-based warm-starting, which augments limited activity measurements with protein language model outputs to improve activity prediction. We also introduce a constant-liar batch selector, which improves batch diversity; this is important in multi-mutation campaigns but had limited effect in our benchmarks. The complete workflow is freely available as open-source software, making efficient protein optimization accessible to any laboratory.
Indexed as
Identifiers
41281216PMC12636759What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.